Injection ozagrel sodium freeze-dried powder for treating cerebral infarction

A technology for ozagrel sodium and injection, which is applied in the field of medicine, can solve problems such as unstable quality of ozagrel sodium freeze-dried powder for injection, non-standard step control process, increased risk of clinical use, etc., to achieve suitable The effect of large production requirements, stable and controllable quality, and fewer types of auxiliary materials
CN105267162AInactive Publication Date: 2016-01-27南京多宝生物科技有限公司
8 Cites 2 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
南京多宝生物科技有限公司
Publication Date
2016-01-27
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses injection ozagrel sodium freeze-dried powder for treating cerebral infarction, and belongs to the technical field of medicines. The ozagrel sodium is a crystal, and the novel crystal form of ozagrel sodium, provided by the invention, is different from a crystal structure of the prior art, and experiments prove that the novel crystal form compound is high in purity, good in fluidity and stability and low in impurity content, cannot absorb moisture easily, is safe and reliable in clinical application; and a powder injection prepared by using the novel crystal form compound is good in stability after being compatible with a solvent and extremely low in insoluble micro-particle content, and is very suitable for clinical application.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of medicine, and relates to a ozagrel sodium freeze-dried powder for injection for treating cerebral infarction. Background technique

[0002] Sodium ozagrel, chemical name: trans-3-4-(1H-imidazolyl-1-methyl)phenyl-2-propenoic acid sodium. This product is a thromboxane (TX) synthase inhibitor, which can prevent prostaglandin H2 (PGH2) from generating thromboxane A2 (TXA2), and promote the transfer of PGH2 derived from platelets to endothelial cells. Endothelial cells are used to synthesize PGI2, thereby improving the abnormal balance of TXA2 and prostaglandin PGI2. In theory, it can inhibit the aggregation of platelets and dilate blood vessels. This product can improve the movement disorder in the acute stage of cerebral thrombosis, improve the circulation disorder in the acute stage of cerebral ischemia and improve the abnormal energy metabolism in cerebral ischemia. Animal experiments have shown that in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More